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ARTICLE
BRCA1/2 testing in newly diagnosed breast and ovarian
cancer patients without prior genetic counselling: the
DNA-BONus study
Hildegunn Høberg-Vetti*,1,2, Cathrine Bjorvatn1,2,3, Bent E Fiane4, Turid Aas5, Kathrine Woie6, Helge Espelid7,
Tone Rusken8, Hans Petter Eikesdal3,9, Wenche Listøl1,2, Marianne T Haavind1, Per M Knappskog2,3,
Bjørn Ivar Haukanes2, Vidar M Steen1,2,3,11 and Nicoline Hoogerbrugge1,10,11
Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the result affects both treatment and
cancer prevention in patients and relatives. Through the DNA-BONus study we offered BRCA1/2 testing and familial risk
assessment to all new patients with breast (N=893) or ovarian (N=122) cancer diagnosed between September 2012 and April
2015, irrespective of family history or age, and without prior face-to-face genetic counselling. BRCA1/2 testing was accepted by
405 (45.4%) and 83 (68.0%) of the patients with breast or ovarian cancer, respectively. A pathogenic BRCA1/2 variant was
found in 7 (1.7%) of the breast cancer patients and 19 (22.3%) of the ovarian cancer patients. In retrospect, all BRCA1/2
mutation carriers appeared to fulﬁll current criteria for BRCA1/2 testing. Hospital Anxiety and Depression Scale (HADS) scores
showed that the mean levels of anxiety and depression were comparable to those reported for breast and gynecological cancer
patients in general, with a signiﬁcant drop in anxiety symptoms during a 6-month follow-up period, during which the test result
was forwarded to the patients. These results show that BRCA1/2 testing is well accepted in newly diagnosed breast and ovarian
cancer patients. Current test criteria based on age and family history are sufﬁcient to identify most BRCA1/2 mutation carriers
among breast cancer patients. We recommend germline BRCA1/2 testing in all patients with epithelial ovarian cancer because of
the high prevalence of pathogenic BRCA1/2 variants.
European Journal of Human Genetics (2016) 24, 881–888; doi:10.1038/ejhg.2015.196; published online 9 September 2015
INTRODUCTION
Breast cancer is by far the most common cancer in women worldwide,
with more than 1.6 million new cases diagnosed each year. Ovarian
cancer is substantially less common, with ∼ 240 000 new cases each
year, but with higher mortality.1 Most cases of breast and ovarian
cancer are sporadic, but a minor fraction (2–8% and 8–15%,
respectively) is caused by inheritance of pathogenic germline variants
in BRCA1 or BRCA2, with variation in prevalence and relative
contribution of BRCA1 and BRCA2 in different populations.2–8 It is
important to identify these patients because the presence of such
germline variants affects treatment, follow-up and further cancer
prevention in patients with breast or ovarian cancer.9,10 In addition, it
may strongly inﬂuence upon their close relatives, as BRCA1/2 testing
can identify healthy BRCA1/2 mutation carriers at high risk and
thereby prevent cancer and cancer-related deaths through increased
surveillance and prophylactic surgery.10–16
The most common current practice of BRCA1/2 testing is based on
referral of suspected high-risk patients to clinical genetics services for
specialized face-to-face genetic counselling. This procedure tradition-
ally includes collection and conﬁrmation of family history, risk
assessment and eventually BRCA1/2 testing followed by a post-test
counselling with dissemination of test results and advice concerning
surveillance and follow-up.17–19 Based on family history, BRCA1/2-
negative families with increased risk of familial breast cancer can also
be identiﬁed.18,20
However, this traditional approach is time consuming and resource
demanding for both the patient and the health-care system, with an
inherent risk of focusing too much on healthy relatives and not
reaching all the cancer patients in question. Moreover, the discovery
that BRCA1/2 status can inform treatment decisions in breast and
ovarian cancer patients has led to an increased demand for BRCA1/2
testing at the time of cancer diagnosis.9,21 New approaches to
BRCA1/2 testing and genetic counselling may be needed to meet this
situation. The aim of this project was therefore to assess the feasibility
and impact of offering BRCA1/2 testing to all newly diagnosed patients
with breast or ovarian cancer without prior face-to-face genetic
counselling. We here report the uptake of BRCA1/2 testing, the
incidence of pathogenic BRCA1/2 variants and the individual risk
proﬁles among these unselected breast and ovarian cancer patients.
As the psychosocial impact of such BRCA1/2 testing in newly
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diagnosed cancer patients without prior genetic counselling is scarcely
described,22 we also examined the symptoms of anxiety and depres-
sion at inclusion and during the follow-up period of 6 months.
PATIENTS AND METHODS
Recruitment of patients
The patients were recruited from four hospitals in Western Norway (Haukeland
University Hospital, Stavanger University Hospital, Haugesund Hospital and
Førde Central Hospital), including three surgical departments and two
gynecological departments, from September 2012 to April 2015. All patients
with newly diagnosed breast or ovarian cancer were invited to participate in the
study (for overview, see Figure 1). The patients received written information on
the project and general information on hereditary breast and ovarian cancer,
including the mode of inheritance and the potential consequences of a positive
test results; such as the elevated cancer risk, recommended follow-up and risk-
reducing strategies for the patient and healthy relatives. They were also
informed that a positive test result could affect the surgical treatment of breast
cancer patients, whereas speciﬁc information on novel therapies, like PARP-
inhibitors, was not given. In addition, the patients had the opportunity to
contact a genetic counselor on telephone for any further questions. All
participants signed informed consent and ﬁlled in a structured questionnaire
on personal and family medical history. The patients could choose BRCA1/2
testing with or without participating in an associated study of psychosocial
aspects (see below). A blood sample was then collected at the local hospital and
sent to a central laboratory for BRCA1/2 analysis. The study protocol was
approved by the Regional Committee for Medical and Health Research Ethics
(reference number REK Vest 2012-60).
DNA isolation, BRCA mutation analysis and clinical assessments
Genomic DNA was puriﬁed from EDTA-anticoagulated blood using the
QiaSymphony instrument (Qiagen, Hilden, Germany). Genotyping of a panel
of 20 pathogenic BRCA1 and 10 pathogenic BRCA2 variants that are recurrent
in the Norwegian population was carried out using TaqMan Low-Density
Arrays on the ABI 9700 instrument (Applied Biosystems, Foster City, CA, USA)
as recommended by the manufacturer. An overview over the variants and
sequences for the corresponding primers and probes is given in the
Supplementary Table 1. In addition, the BRCA1 and BRCA2 genes were
analyzed for deletions and insertions by Multiplex Ligation-dependent Probe
Ampliﬁcation (MLPA) technology (P002 BRCA1 and P045 BRCA2 MLPA
probe mixes; MRC-Holland, Amsterdam, The Netherlands).
The result of the BRCA1/2 testing was given to the patient by a genetic
counselor within 3 weeks after blood sample collection (Figure 1). In addition,
the result was reported to the clinician who was responsible for treating the
patient, to be ﬁled in the patient’s medical record at the hospital. If the test
result was negative and there was no increased familial cancer risk, the patient
received the result by letter. Patients with a positive test result or with a
personal or family history indicative of a high risk of hereditary cancer were
contacted over the phone by a genetic counselor and were offered traditional
face-to-face genetic counselling and further investigations in one of our
outpatient clinics.
Based on collection of family history and conﬁrmation of cancer diagnoses in
relatives, selected patients were then offered extended genetic testing, with
Sanger sequencing of all exons and ﬂanking intron sequence in both BRCA1
and BRCA2. We used the following reference sequences: BRCA1: NG_005905.2
(gene), NM_007294.3 (mRNA), NP_009225.1 (protein); BRCA2: NG_012772.3
(gene), NM_000059.3 (mRNA) and NP_000050.2 (protein)).
To classify the sequence variants we followed the recommendations given by
the International Agency for Research on Cancer (IARC).23 Pathogenic (class 5)
and likely pathogenic (class 4) variants were regarded as positive genetic test
results and have been submitted to the Leiden Open Variation Database
(LOVD 3.0 shared installation; www.databases.lovd.nl/shared/genes). In this
article we use the term BRCA1/2 mutation carrier for patients in whom a
pathogenic or likely pathogenic variant was found.
All patients were categorized before BRCA1/2 testing depending on the
presence of increased familial cancer risk or not. Increased risk was deﬁned as
personal at risk cancer history (eg, patients with young age at diagnosis, bilateral
breast cancer or both breast and ovarian cancer) or positive family history
(eg, close relative with breast cancer before 50 years of age or ovarian cancer at
any age, two or more relatives with breast cancer or both breast and ovarian
cancer in relatives) or a combination of personal at risk cancer history and
positive family history, according to the current national clinical criteria for
BRCA1/2 testing (see also legend to Table 1). The participants were in addition
rated by the Manchester scoring system for BRCA1/2 testing.24,25
Psychological measurements
Participants who gave informed consent for the psychosocial part of the project
were asked to ﬁll in questionnaires at baseline when they were offered genetic
testing (T1), at 1 week after disclosure of the BRCA1/2 test result (T2) and
6 months after disclosure of the BRCA1/2 test result (T3). In the present study,
we have used data from the Hospital Anxiety and Depression Scale (HADS).26
HADS comprises two subscales for symptoms of anxiety and depression,
respectively, each with 7 items to be scored on a 4-point (0–3) scale, giving a
range of subscores from 0 to 21. The reliability of the HADS subscales in this
study, as estimated with Cronbach’s α, had a range of 0.83–0.88 for HADS
anxiety and 0.80–0.86 for HADS depression at the three assessments. Subscale
scores of ≥ 8 were used as cutoff for deﬁning higher, caseness-relevant levels of
anxiety and depression.27
Statistical methods
Descriptive statistics were used for psychological and clinical variables,
reporting the mean values, SD and range. To analyze the changes over time
in HADS anxiety and depression scores, we used a paired sample t-test and
McNemar’s exact test. Independent sample t-test was used to compare the
means of two independent groups and χ2 test was used to analyze dichotomous
variables for independent groups.
Missing values were replaced by the individual’s own average score for HADS
if 60% or more of the items were ﬁlled in by the respondents. All statistical
Genetic test for recurrent pathogenic
variants in BRCA1/BRCA2
Normal test
result
Negative history
Patient receives a phone call from a
genetic counselor and is invited for
genetic counselling and/or
further genetic testing
Patient is informed of
the result by a
letter from the
genetic counselor
All newly diagnosed patients
with breast or ovarian cancer
Normal test result
Personal or family history indicating
high risk of hereditary cancer
Pathogenic
variant
found
Written information about
the project
Blood sampling at the
clinical department
Analysis result report is sent to
the genetic department
The patient’s physician receives
a copy of the result report
Figure 1 Flowchart showing the inclusion of patients and reporting of results
in the DNA-BONus study.
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analyses were performed using IBM SPSS Statistics for Windows, Version 22.0
(Armonk, NY, USA).
RESULTS
A total of 1015 patients with either breast cancer (N= 893) or ovarian
cancer (N= 122) were offered BRCA1/2 testing at the time of cancer
diagnosis, of whom 405 (45.4%) of the breast cancer patients and 83
(68.0%) of the ovarian cancer patients completed the genetic testing.
The mean age of the participants was 56.9 years (SD 12.4, range
(min–max) 23–89) in the patients with breast cancer and 60.5 years
(SD 11.9, range 24–88) in the patients with ovarian cancer (Table 1).
Among the participants, 202 (49.9%) of the patients with breast cancer
and 70 (84.3%) of the patients with ovarian cancer were eligible for
BRCA1/2 testing according to current national clinical guidelines
(Table 1). The median time from diagnosis to blood sampling was
34 days (mean 68, range 0–1402) and the median time from diagnosis
to the patient received initial test result was 52 days (mean 87, range
12–1423) (data not shown). For 13 patients, the interval between
diagnosis and blood sampling exceeded 1 year.
A pathogenic BRCA1/2 variant was identiﬁed in 7 (1.7%) of the 405
breast cancer patients (mean age of 50.6 (SD 15.8, range 32–76) years;
Table 1), of whom 6 carried a BRCA1 and 1 a BRCA2 pathogenic
variant (Table 2). Three BRCA1 and one BRCA2mutation carriers had
a breast cancer that was triple negative (Er-/Pr-/HER2-) and all seven
breast cancers were HER2 negative (Table 2). Interestingly, as many as
19 (22.3%) of the 83 ovarian cancer patients (mean age 56.5 (SD 9.1,
range 44–72) years) were BRCA1/2 mutation carriers (Table 1),
including 15 with a pathogenic BRCA1 variant and 4 patients with a
pathogenic BRCA2 variant (Table 2). Most ovarian cancers were
serous carcinomas, apart from one poorly differentiated carcinoma
and one endometroid adenocarcinoma. The majority of the mutation
carriers (N= 21; 80.8%) were identiﬁed by the standard test panel of
recurrent mutations (Table 2), where 3 of the most frequent
Norwegian pathogenic founder variants in BRCA1 (c.1556del,
c.697_698del and c.3228_3229del) were detected in 15 (57.7%) of
the mutation carriers. Four additional pathogenic variants were
identiﬁed by Sanger sequencing of selected breast cancer (N= 94) or
ovarian cancer (N= 31) patients with a particularly high risk of
carrying a pathogenic BRCA1/2 variant, based on the personal and
family history (see Table 2). During the ﬁrst (years 2012–2013) and
second (years 2014–2015) half of the DNA-BONus study period,
26.1% (55 out of 211) and 25.3% (70 out of 277) of the participants
were selected for Sanger sequencing, respectively. Out of the total
population of 488 patients, no one had BRCA1/2 alterations that could
be detected by MLPA.
Among the 272 patients fulﬁlling the current national criteria for
diagnostic BRCA1/2 testing at inclusion, 6 out of 202 breast cancer
patients (3.0%) and 18 out of 70 ovarian cancer patients (25.7%) were
found to be mutation carriers (Table 1). Among 216 patients not
meeting current clinical test criteria at inclusion, the corresponding
numbers of BRCA1/2 mutation carriers were 1 of the 203 breast
cancer patients (0.5%) and 1 of the 13 ovarian cancer patients (7.7%).
However, it should be noted that the breast cancer patient with a
pathogenic BRCA1 variant and the ovarian cancer patient with a
pathogenic BRCA2 variant, who apparently had negative family
histories upon inclusion, were both subsequently reclassiﬁed as having
familial risk, based on extended pedigrees obtained through the
genetic counselling (see below, Discussion section).
The mean combined Manchester score at inclusion was 8.9 (range
2–71) (data not shown), with 67 out of 488 patients (13.7%) having a
score of ≥ 15 (Table 1). A pathogenic BRCA1/2 variant was found in
13 out of 67 patients (19.4%) with a score of ≥ 15 and in 13 out of 421
patients (3.1%) with a score o15 (Table 1; summarized numbers).
Among the 26 BRCA1/2 mutation carriers, the mean combined
Manchester score at inclusion was 19.5 (range 4–71) (Table 2;
summarized numbers). After genetic counselling and collection of
additional clinical information, including pathology reports, the scores
could be recalculated for 25 of the 26 mutation carriers (Table 2). The
mean combined score increased to 27.7 (range 14–81) (data not
shown), with 24 mutation carriers having a score of ≥ 15, whereas the
remaining mutation carrier had a score of 14 (Table 2).
All 26 BRCA1/2 mutation carriers accepted the offer of traditional
face-to-face post-test genetic counselling. Among participants with a
negative result on the initial BRCA1/2 panel and MLPA analysis,
genetic counselling was offered for 188 patients (40.3% of total) with a
personal at risk cancer history indicating further genetic testing
(eg, young age at diagnosis or more than one primary cancer) or
with a positive family history indicative of either familial breast cancer
(eg, two or more breast cancer cases in ﬁrst-degree relatives) or
another hereditary cancer syndrome. The acceptance rate for genetic
counselling in this group was 93.6% (N= 176).
Because of the potential risk of imposing additional psychosocial
burden by offering and performing BRCA1/2 testing in the newly
diagnosed cancer patients, we measured the level of anxiety and
depression scores before testing and at 1 week and 6 months after
disclosure of the test result in a subset of participants (Table 3).
Among these 215 patients, the median time from diagnosis to blood
sampling was 32 days (mean 56, range 0–436) and median time from
diagnosis to received result was 50 days (mean 75, range 12–456) (data
not shown). The mean HADS subscale score for anxiety symptoms
was 6.84 (SD 4.28) at baseline (ie, time of inclusion), with a signiﬁcant
decrease to 4.88 (SD 3.86) 6 months after disclosure of the BRCA1/2
test result (Po0.001). The percentage of patients with higher levels of
anxiety symptoms, deﬁned as scores ≥ 8, decreased signiﬁcantly from
inclusion (39.9%) to 1 week (23.6%, Po0.001) and 6 months (19.8%,
Po0.001) after disclosure of the test result, respectively. During the
observation period there was no signiﬁcant change in depression
symptoms, with a mean HADS score of 3.32 (SD 3.07) at baseline and
2.65 (SD 3.04) at 6 months. Approximately 10% of the patients
showed higher levels of depression symptoms with a score of ≥ 8, both
at baseline and follow-up measurements (Table 3). There were no
signiﬁcant differences in HADS scores between patients with breast
(N= 138) and ovarian (N= 29) cancer, or between mutation carriers
(N= 8) and noncarriers (N= 159) (data not shown).
To explore the effect of time after diagnosis on the HADS scores, we
divided the sample in two groups, with N= 171 (83.0%) having less
than and N= 35 (17.0%) having more than 90 days from cancer
diagnosis to blood sampling. There were no signiﬁcant differences in
HADS scores between the two groups (data not shown).
Compared with the participants who only agreed to genetic testing
(mean age 61.6 years), the patients who also took part in the
psychosocial study were signiﬁcantly younger (Po 0.001), with a
mean age of 56.2 years (data not shown). There were no signiﬁcant
differences between the two groups regarding educational level or type
of cancer diagnosis (breast or ovarian).
DISCUSSION
The main ﬁndings in this study are that: (1) most patients with newly
diagnosed ovarian cancer accept germline BRCA1/2 testing, with
signiﬁcantly lower uptake among breast cancer patients; (2) there is
a high prevalence of BRCA1/2 mutation carriers in the group of
ovarian cancer patients; (3) all patients who were identiﬁed with a
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pathogenic BRCA1/2 variant fulﬁll our current clinical criteria for
diagnostic BRCA1/2 testing; and (4) the level of anxiety and depression
symptoms in the participants at inclusion was comparable to what can
be found in cancer patients in general.28,29
Ovarian and breast cancer patients with pathogenic BRCA1/2
variants are candidates for targeted drug therapy, such as PARP
inhibitors.21 Recently, the US Food and Drug Administration (FDA)
approved a PARP inhibitor for use in ovarian cancer (http://www.fda.
gov/newsevents/newsroom/pressannouncements/ucm427554.htm).
Our study shows that, even before such treatment options became
available, BRCA1/2 testing was well accepted among newly diagnosed
patients, with 68% participation rate among the women with ovarian
cancer, whereas 45% of patients with breast cancer chose to undergo
BRCA1/2 testing. There may be a selection bias among the participants
because, on average, patients with breast cancer and ovarian cancer in
our study were younger (mean age 56.9 and 60.5 years, respectively) as
compared with patients with these cancers in the Norwegian popula-
tion in general. According to national numbers, the mean age of all
cases with breast cancer and ovarian cancer diagnosed between 2008
and –2012 was 61.5 and 65.4 years, respectively,30 thereby indicating
that older patients may have declined participation in our study. This
could be particularly relevant for breast cancer patients with low
a priori risk of carrying a pathogenic BRCA1/2 variant. The assump-
tion of a certain degree of risk-based selection in the uptake is further
supported by the fact that among the participants, 50% of the patients
with breast cancer and480% of the patients with ovarian cancer were
eligible for diagnostic BRCA1/2 testing according to the current
clinical guidelines. For obvious reasons the uptake will be higher
when the result of BRCA1/2 testing inﬂuences treatment options.21
In total, we identiﬁed 26 patients with a pathogenic BRCA1/2
variant and by that identiﬁed 22 new BRCA1/2 families. This ﬁnding
supports a need for increased availability and use of such BRCA1/2
testing, as a supplement to the existing referral systems and service in
cancer genetics. Our study also reports a high prevalence (22.3%) of
pathogenic BRCA1/2 variants in ovarian cancer patients, substantially
higher than reported by others.3–5 This may be caused by a high
prevalence of pathogenic founder variants in our population, but
surprisingly the prevalence among patients with breast cancer is rather
low (1.7%) compared with international data.2,6 The highest pre-
valence of BRCA1/2 mutation carriers has been reported in popula-
tions with very strong founder effects, and most studies on the
frequency of pathogenic BRCA1/2 variants in patients with sporadic
breast cancer have had some form of selection criteria, for example,
young age at onset or triple-negative histology.2,7,8 In the DNA-
BONus study, we offered genetic testing to all patients with newly
diagnosed breast cancer that, in combination with a rather low
prevalence of pathogenic BRCA2 variants in the Norwegian
population,6 at least in part may explain the rather low frequency of
pathogenic BRCA1/2 variants among our patients with breast cancer.
At inclusion, all but two of the 26 BRCA1/2 mutation carriers
fulﬁlled the current clinical recommendations for diagnostic BRCA1/2
testing in Norway. One patient with breast cancer after the age of 75
years apparently had a negative family history according to the
information forwarded at inclusion. However, further examination
revealed that her sister died from ovarian cancer before the age of 50
years. The other patient was a woman with ovarian cancer after the age
of 70 years. We were informed at inclusion that she had two ﬁrst-
degree relatives with abdominal cancer and cervical cancer, respec-
tively, both after the age of 70 years. During the genetic counselling
these diagnoses were both conﬁrmed to be ovarian cancer cases.
Thus, all mutation carriers in this study fulﬁlled current nationalTa
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criteria for diagnostic BRCA1/2 testing when a proper personal and
family history had been taken.
The Manchester scoring system is a frequently used tool to identify
individuals and families at high risk of having a pathogenic BRCA1/2
variant.24 In this study, we found that the Manchester scores obtained at
inclusion were markedly lower than the real values (see below). In
retrospect, all BRCA1/2 mutation carriers had combined Manchester
scores at ≥ 14 points, demonstrating that the hereditary breast and
ovarian cancer families identiﬁed through testing of patients with inci-
dental breast or ovarian cancer do not differ signiﬁcantly from families
identiﬁed through the traditional route. These ﬁndings indicate that
most BRCA1/2 mutation carriers can be identiﬁed through evidence-
based clinical criteria, also within a group of incidental patients.
In order to identify patients at risk of non-BRCA1/2 familial breast
cancer and other causes of hereditary cancer, we systematically
collected structured family history from the participants before
BRCA1/2 testing and employed a low threshold for our genetic
counselors to contact the participants for additional information.
Indeed, the importance of family history should not be neglected when
the availability of BRCA1/2 testing increases and more patients with
breast cancer are tested in routine clinical practice. Most familial
breast cancer risk is not caused by pathogenic BRCA1/2 variants, and
women belonging to BRCA1/2-negative breast cancer families are also
at increased risk for breast cancer.20 The importance of obtaining a
structured family history was illustrated by the fact that BRCA1/2
mutation carriers in our study scored signiﬁcantly higher in the
Manchester scoring system when taking into account the information
collected during the genetic counselling procedure, as compared with
the rating based on the initial self-reported information. In this regard,
oncologists and surgeons may need additional support and training to
extract a structured and relevant family history.31,32
The traditional genetic counselling procedure has obvious beneﬁts
with respect to high-quality family history collection, and it has been
shown to increase cancer-related knowledge and decrease distress in
newly diagnosed cancer patients with an elevated risk of hereditary
cancer.33 However, because this procedure is resource demanding,
alternative approaches are needed when treatment-driven genetic
testing is offered to larger patient groups with lower probability of
carrying a pathogenic BRCA1/2 variant. Written, telephone-based or
digital information provided by a clinical geneticist or genetic
counselor, together with adequate information from the oncologist
or surgeon, could be considered as an alternative for some patients.22
Patients at increased risk of psychosocial distress should have easy
access to genetic counselling. An open telephone line to a genetic
counselor might not be optimal for patients newly diagnosed with
cancer, as we experienced that o20 patients actually contacted the
genetic counselor for more information before testing throughout the
whole DNA-BONus study period of two-and-a-half years. In order to
discuss the consequences of the BRCA1/2 test results for the patient
and other family members, as well as to explain complex test results
and other hereditary causes of cancer, we also advise genetic
counselling in case of a positive BRCA1/2 test result and in case of a
personal or family history suggestive of hereditary cancer.
As the most common current practice of BRCA1/2 testing is based
on referral of selected high-risk subjects to extensive face-to-face
procedures of genetic counselling before BRCA1/2 testing,17,18 we
investigated whether our new simpliﬁed approach could lead to
increased anxiety or depression in the newly diagnosed patients.
Interestingly, the level of anxiety symptoms was comparable to those
reported for patients with breast cancer and gynecological cancer in
general,28,29 but higher than normal population values.34 Approxi-
mately 40% of the patients had a HADS subscale score above the
deﬁned threshold for symptoms of anxiety27 at inclusion, and the level
of anxiety decreased signiﬁcantly during the 6-month follow-up period
that also included the dissemination of the BRCA1/2 test result. The
drop in the level of anxiety symptoms during the observation period
may simply reﬂect the adjustment to the cancer diagnosis and
treatment, and genetic testing in our study did not appear to inﬂuence
on this expected drop.
There are some limitations to our study. Because of ethical
regulations, we had no information about the patients who declined
participation in the study. Another limitation is that Sanger sequen-
cing of the BRCA1/2 genes was only performed on selected high-risk
patients, implying that some of the lower-risk patients could be
carriers of rare BRCA1/2 variants that were not covered by the
BRCA1/2 panel test. In this respect, it should be noted that the
methods and two-step procedure for BRCA1/2 testing (ie, multiplex
panel test for recurrent variants, plus optional BRCA1 plus BRCA2
Table 3 HADS anxiety and depression subscale scores at various time points for a subset of DNA-BONus participants
At inclusion
One week after disclosure
of genetic test result
Six months after disclosure
of genetic test result
(T1) (T2) (T3)
HADS anxiety
No. of patients 213 191 167
Subscore mean (SD) 6.84 (4.28) 5.29a (4.06) 4.88b (3.86)
Score ≥8 (%) 39.9 23.6c 19.8d
HADS depression
No. of patients 215 190 169
Subscore mean (SD) 3.32 (3.07) 2.90e (3.30) 2.65f (3.04)
Score ≥8 (%) 10.2 10.0 g 10.7h
Abbreviation: HADS, Hospital Anxiety and Depression Scale.
aT1 vs T2: Po0.001.
bT1 vs T3: Po0.001; paired sample t-test.
cT1 vs T2: Po0.001.
dT1 vs T3 Po0.001; McNemar’s exact test.
eT1 vs T2: P=0.32.
fT1 vs T3: P=0.11; paired sample t-test.
gT1 vs T2: P=1.00.
hT1 vs T3: P=0.42; McNemar’s exact test.
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Sanger sequencing) remained unchanged during the whole inclusion
period, and that the fraction of patients who were sequenced was
almost the same in the ﬁrst and second half of the DNA-BONus study.
Another potential weakness is that patients with previously known
pathogenic BRCA1/2 variants, who were diagnosed with cancer during
the DNA-BONus study period, might have declined participation
because of low relevance, thereby reducing the total count of BRCA1/2
mutation carriers among the participants. Finally, some of the psycho-
social results are limited by a small number of participating BRCA1/2
mutation carriers and should therefore be interpreted with caution.
In conclusion, we show that BRCA1/2 mutation testing is well
accepted among patients with newly diagnosed breast or ovarian
cancer. We further conclude that current clinical guidelines are
sufﬁcient to identify the majority of the BRCA1/2 mutation carriers
among patients with breast cancer. Because of the high prevalence of
pathogenic BRCA1/2 variants, we recommend that all patients with
epithelial ovarian cancer are offered germline BRCA1/2 testing,
irrespective of age or family history of cancer.
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